Ascidian Therapeutics

NEWS

Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto

Policy

FDA Clears Ascidian for First-Ever RNA Editing Trial in US

Ascidian Therapeutics, a member of BioSpace’s NextGen Class of 2024, on Monday announced it received IND clearance from the FDA and was granted Fast Track designation for ACDN-01.

January 30, 2024

2 min read

Tyler Patchen

Business

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.

January 3, 2024

20 min read

BioSpace Editorial Staff

IN THE PRESS

Genetown

Ascidian Therapeutics to Present Preclinical Data for RNA Exon Editor, ACDN-01, Supporting an Open IND for Phase 1/2 Clinical Testing at ASGCT 2024 Annual Meeting

April 25, 2024

3 min read

Business

Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO

November 8, 2023

3 min read

AWARDS

JOBS